They Thought Hemophilia Was a ‘ Lifelong Thing. ’ They May Be Wrong.
Experimental gene therapies have yielded promising results in early trials. But the drugs have left some patients wary, worried that success will not last. (Source: NYT Health)
Source: NYT Health - August 13, 2018 Category: Consumer Health News Authors: GINA KOLATA Tags: Hemophilia Genetics and Heredity Blood Proteins Drugs (Pharmaceuticals) Clinical Trials Biotechnology and Bioengineering Source Type: news

Orchard raises $150 million to expand after GSK gene therapy deal
Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million. (Source: Reuters: Health)
Source: Reuters: Health - August 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

St. Jude and Mustang Bio enter into exclusive worldwide license agreement
A partnership between St. Jude and Mustang Bio may change the challenges faced by those diagnosed with what is commonly referred to as “bubble boy disease.” Memphis' St. Jude Children’s Research Hospital and New York-based Mustang Bio Inc. have entered into an exclusive worldwide license agreement to develop a first-in-class gene therapy for X-linked severe combined immunodeficiency (X-SCID). The rare and sometimes fatal dis ease affects one in every 50,000 to 100,000 newborns and is the most… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 13, 2018 Category: Pharmaceuticals Authors: Jason Bolton Source Type: news

Amish nemaline myopathy natural history study finds promise for gene therapy treatment
(Clinic for Special Children) A new comprehensive natural history study about Amish nemaline myopathy (ANM) in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder. Amish nemaline myopathy (ANM) is an infantile-onset muscle disease linked to a mutation of the TNNT1 gene. The study summarizes genealogical records, clinical data, and molecular reports of one hundred and six ANM patients born between 1923 and 2017 and was led by researchers from the Clinic for Special Children in Strasburg, Pa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2018 Category: International Medicine & Public Health Source Type: news

Injection of novel gene therapy vector prolonged survival in mouse model of Pompe disease
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study has shown that a single injection of a novel adeno-associated vector (AAV)-based therapy can result in improved enzyme activity and glycogen clearance as well as prolonged survival in a mouse model of Pompe disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2018 Category: International Medicine & Public Health Source Type: news

Why is the Trump administration using billions in taxpayer dollars to subsidize GMO agriculture?
(Natural News) When President Trump first took office, there was renewed hope among anti-GMO activists that he would take positive action to curtail the $350 billion-a-year biotechnology industry. After all, both on the campaign trail and for the first 353 days of his presidency he never mentioned the words biotechnology, CRISPR, eugenics, gene therapy or... (Source: NaturalNews.com)
Source: NaturalNews.com - August 12, 2018 Category: Consumer Health News Source Type: news

Backed with $140M, startup launches three-pronged attack on liver diseases
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker. Ambys Medicines Inc. will get $100 million from Takeda Pharmaceutical Co. Ltd. — including $80 million in research and development commitments — on top of $40 million from Third Rock to pursue cell therapy, gene therapy and traditional small-molecule approaches to restoring and replacing live r function lost in a variety… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 8, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

OHSU's Mitalipov confirms earlier gene editing breakthrough after critics raise doubts
Just weeks after an Oregon Health& Science University biologist published a paper last August about a gene editing breakthrough, a group of outside scientists began to raise doubts about the results. A year later, Shoukhrat Mitalipov, director of OHSU’s Center for Embryonic Cell and Gene Therapy, is out with another paper, again in the journal Nature, verifying his earlier findings. Led by Mitalipov, an international team of researchers re-tested embryonic samples they generated in the fir st… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 8, 2018 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

RegenXBio Gene Therapy Shows Early Promise For Eye Disease; Cholesterol Treatment Results Mixed
A gene therapy being developed by RegenX Bio of Rockville, MD, showed early promise against wet macular degeneration, a leading cause of blindness. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 8, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:RGNX Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Why this company's Durham outpost may benefit from $100M investment
Massachusetts-based gene therapy company bluebird bio (Nasdaq: BLUE) – which is growing in Durham – has inked a $100 million deal for the development of treatments for cancer. Bluebird said Monday that it will collaborate with New York-based Regeneron Pharmaceuticals (Nasdaq: REGN) on those potential treatments and that, as part of the deal, Regeneron will make a $100 million investment in the company’s common stock “at a price of $238.10 per share, which represents a premium of 59 percent… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 7, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Why Spark's stock price is down 30 percent
Despite posting its first-ever profitable quarter, shares of Spark Therapeutics were trading down 30 percent Tuesday morning after the Philadelphia gene therapy company reported two patients had an adverse immune response to its experimental hemophilia A therapy. Spark said the immune response problem was addressed and it is moving forward with late-stage testing of the treatment, known as SPK-8011 that will begin by the end of the year. Hemophilia A is a genetic bleeding disorder caused by missing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 7, 2018 Category: Biotechnology Authors: John George Source Type: news

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC) - consisting of Imperial College London and the Universities of Oxford and Edinburgh - Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). (Source: World Pharma News)
Source: World Pharma News - August 7, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

How a gene breakthrough has saved Joe's sight
Joe Pepper was diagnosed with choroideremia when he was just ten years old. The disease  causes progressive sight loss, but pioneering gene therapy saved him. This is his story. (Source: the Mail online | Health)
Source: the Mail online | Health - August 6, 2018 Category: Consumer Health News Source Type: news

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron Pharmaceuticals, one of the largest biotechnology companies, and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 6, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:REGN NASDAQ:BLUE Source Type: news

Regeneron And Bluebird Team Up To Invent New Cell Therapies For Cancer
Regeneron Pharmaceuticals, one of the largest biotechnology companies, and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 6, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:REGN NASDAQ:BLUE Source Type: news

New Partnership to Develop Gene Therapy for Cystic Fibrosis
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 6, 2018 Category: Research Source Type: news

Cover Story: Triangle plunges into transformational science
The U.S. Food and Drug Administration is watching closely as new gene therapy technologies take root. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 3, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

Gene Therapy Restores Sense of Smell in Mouse Model Gene Therapy Restores Sense of Smell in Mouse Model
Gene therapy can restore the sense of smell in mice lacking Ift88, a gene necessary for normal ciliary function of olfactory sensory neurons, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bracco signs CT research deal with Duke
Contrast developer Bracco Imaging has formed a CT research collaboration with...Read more on AuntMinnie.comRelated Reading: Bracco's SonoVue ultrasound contrast cleared in China Bracco collaborates again with Shanghai Pharmaceuticals Bracco hits Jubilant with patent complaint on rubidium PET Bracco lands new FDA approval for MultiHance Bracco targets gene therapy for ultrasound contrast (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 31, 2018 Category: Radiology Source Type: news

AHA: Scientists May Have Cleared Gene Therapy Hurdle
TUESDAY, July 31, 2018 (American Heart Association) -- Scientists may have found a way to slip a special type of disease-fighting virus past the guard of the body's immune system and into targeted cells where it can do its intended work, according... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 31, 2018 Category: General Medicine Source Type: news

Alliance for Cancer Gene Therapy (ACGT) takes on solid tumor cancers
(Alliance for Cancer Gene Therapy) ACGT provides $1.5 million in cancer gene therapy grants to tackle solid tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2018 Category: Cancer & Oncology Source Type: news

Chinese researchers further develop adenine base editing system
(Springer) Two research teams from East China Normal University and Sun Yat-Sen University in China have developed and improved the ABE system in mouse and rat strains, which has great implications for human genetic disorders and gene therapy. The research has been published by Springer Nature in two articles in the open access journal Protein& Cell. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 31, 2018 Category: Biology Source Type: news

'Serendipitous' discovery at OHSU primate center may speed gene therapy
Researchers discovered a naturally occurring form of a deadly childhood neurodegenerative condition in a small population of macaque monkeys at the Oregon National Primate Research Center. The discovery provides a unique — and unexpected — opportunity for Oregon Health& Science University scientists to develop gene-therapy treatments to stop the progression of Batten disease. “It was accidental, but I’ve been calling it serendipitous, in the sense that we didn’t breed these animals to… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 30, 2018 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

'Serendipitous' discovery at OHSU primate center may speed gene therapy
Researchers discovered a naturally occurring form of a deadly childhood neurodegenerative condition in a small population of macaque monkeys at the Oregon National Primate Research Center. The discovery provides a unique — and unexpected — opportunity for Oregon Health& Science University scientists to develop gene-therapy treatments to stop the progression of Batten disease. “It was accidental, but I’ve been calling it serendipitous, in the sense that we didn’t breed these animals to… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 30, 2018 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

DNA repair after CRISPR cutting not at all what people thought
(University of California - Berkeley) UC Berkeley scientists discovered that a well-known DNA repair pathway, the Fanconi anemia pathway, surprisingly plays a key role in repairing double-strand DNA breaks created by CRISPR-Cas9. It acts as a traffic cop to steer repair to simple end-joining or to patching the cut with new, single-strand DNA. Scientists could potentially tweak proteins involved in the pathway to preferentially steer the outcome toward replacement with DNA, which is important for gene therapy for hereditary diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 30, 2018 Category: Cancer & Oncology Source Type: news

Scientists discover neurodegenerative disease in monkeys
(Oregon Health& Science University) OHSU scientists have discovered a naturally occurring disease in monkeys that mimics a deadly childhood neurodegenerative disorder in people -- a finding that holds promise for developing new gene therapies to treat Batten disease. Scientists confirmed through genetic analysis that a small population of Japanese macaque monkeys carry a mutation in the CLN7 gene that causes one form of the disease. It's the only known model for the disease among non-human primates in the world. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2018 Category: International Medicine & Public Health Source Type: news

A fight for sight that we all need to join | Letters
Betty Boothroyd, former Speaker of the House of Commons, calls for more research funding for eye healthRe your article on age-related macular degeneration (G2, 16 July), this week the eye research charityFight for Sight is launching a campaign to raise awareness of eye health and the desperate need for more research funding. This is an issue close to my heart. Many people of my age are starting to have difficulty with their sight and over 2 million people in the UK are affected by sight loss – a figure set to double by 2050. The answer lies in research. Breakthroughs have already led to pioneering treatment...
Source: Guardian Unlimited Science - July 24, 2018 Category: Science Authors: Letters Tags: Medical research Society Health Science Source Type: news

Biogen shares jump despite mixed news on rare disease drugs
Biogen shares jumped Tuesday after the company reported strong revenue from its rare disease drug Spinraza, despite announcing a setback with a gene therapy treatment targeting the same disorder. Biogen (Nasdaq: BIIB), which is scheduled to release highly anticipated data from an Alzheimer's drug trial on Wednesday, said that its revenue jumped to $3.4 billion in the second quarter, a 9 percent increase over the same period last year. Sales of Spinraza, a treatment for spinal muscular atro phy, or… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 24, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Biotech PTC to acquire Lynnfield's Agilis in $200M deal
New Jersey-based drug developer PTC Therapeutics Inc. announced Thursday that it is purchasing Agilis Biotherapeutics Inc., a Lynnfield gene therapy biotech, for $200 million in cash and stock. PTC (Nasdaq: PTCT) said it would pay $50 million in cash and $150 million in PTC stock to acquire Agilis. The privately held biotech is developing gene therapies for rare and often fatal nervous system diseases, including a disorder called AADC Deficiency that inhibits motor control and the abili ty to swallow… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 19, 2018 Category: American Health Authors: Allison DeAngelis Source Type: news

Biotech PTC to acquire Lynnfield's Agilis in $200M deal
New Jersey-based drug developer PTC Therapeutics Inc. announced Thursday that it is purchasing Agilis Biotherapeutics Inc., a Lynnfield gene therapy biotech, for $200 million in cash and stock. PTC (Nasdaq: PTCT) said it would pay $50 million in cash and $150 million in PTC stock to acquire Agilis. The privately held biotech is developing gene therapies for rare and often fatal nervous system diseases, including a disorder called AADC Deficiency that inhibits motor control and the abili ty to swallow… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 19, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
Pfizer Inc. said Monday it has started late-stage clinical testing of an experimental gene therapy treatment, originally developed by Spark Therapeutics in Philadelphia, for patients with hemophilia B. The transfer of the gene therapy program to Pfizer from Spark is now complete, the companies said. Under the terms of a product license agreement signed in December 2014, Pfizer has now assumed sole responsibility for all subsequent pivotal studies, all regulatory activities, manufacturing and gl obal… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 16, 2018 Category: American Health Authors: John George Source Type: news

Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
Pfizer Inc. said Monday it has started late-stage clinical testing of an experimental gene therapy treatment, originally developed by Spark Therapeutics in Philadelphia, for patients with hemophilia B. The transfer of the gene therapy program to Pfizer from Spark is now complete, the companies said. Under the terms of a product license agreement signed in December 2014, Pfizer has now assumed sole responsibility for all subsequent pivotal studies, all regulatory activities, manufacturing and gl obal… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2018 Category: Biotechnology Authors: John George Source Type: news

Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy
Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for (Source: World Pharma News)
Source: World Pharma News - July 16, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Fetal gene therapy prevents fatal neurodegenerative disease
(SingHealth) A fatal neurodegenerative condition known as Gaucher disease can be prevented in mice following fetal gene therapy, finds a new study led by UCL, the KK Women's and Children's Hospital and National University Health System in Singapore.The study, published today in Nature Medicine, highlights the potential of fetal gene therapy to prevent and cure neonatal lethal neurodegenerative diseases in humans in utero. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2018 Category: International Medicine & Public Health Source Type: news

Genome damage from CRISPR/Cas9 gene editing higher than thought
(Wellcome Trust Sanger Institute) Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. This has safety implications for future gene therapies using CRISPR/Cas9 as the unexpected damage could lead to dangerous changes in some cells.The study in Nature Biotechnology revealed that standard DNA tests miss finding this genetic damage, and that caution and specific testing will be required for any potential gene therapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 16, 2018 Category: Biology Source Type: news

FDA issues new gene therapy guidances
FDA ’s CBER issued a suite of six scientific guidance documents intended to serve as a framework for gene therapies. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 13, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Type 2 diabetes, obesity may soon be reversed with gene therapy
For the first time, scientists use gene therapy to successfully reverse obesity and insulin resistance in an animal model of type 2 diabetes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2018 Category: Consumer Health News Tags: Diabetes Type 2 Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D. on agency ’ s efforts to advance development of gene therapies
Statement from FDA Commissioner Scott Gottlieb, M.D. on agency ’ s efforts to advance development of gene therapies, including three disease specific draft guidances (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 11, 2018 Category: American Health Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D. on agency ’s efforts to advance development of gene therapies
Statement from FDA Commissioner Scott Gottlieb, M.D. on agency ’s efforts to advance development of gene therapies, including three disease specific draft guidances (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 11, 2018 Category: American Health Source Type: news

Gene therapy successfully reverts obesity and type-2 diabetes
According to a new study inEMBO Molecular Medicine, a single administration of a viral vector to mouse models of obesity can induce weight loss and decrease insulin resistance.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 10, 2018 Category: Endocrinology Source Type: news

Gene therapy used to control diabetes, reduce obesity in mice
In one administration of gene therapy, researchers caused weight loss in mice and lowered insulin resistance, curing obesity and type 2 diabetes in the rodents. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2018 Category: Consumer Health News Source Type: news

Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
More and more researchers are conducting clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments. (Source: The Scientist)
Source: The Scientist - July 9, 2018 Category: Science Tags: Infographics Source Type: news

UAB researchers cure type 2 diabetes and obesity in mice using gene therapy
(Universitat Autonoma de Barcelona) A single administration of a therapeutic vector in mouse models cures type 2 diabetes and obesity in the absence of long-term side effects. In healthy mice, the therapy prevents age-associated weight gain and insulin resistance and promotes healthy aging. The research constitutes the basis to support the future clinical translation of a gene therapy for these metabolic diseases in humans and is published today in EMBO Molecular Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2018 Category: International Medicine & Public Health Source Type: news

eBook: Aseptic Processing Trends
With the rising demand of gene therapies, aseptic processing practices are changing rapidly (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 2, 2018 Category: Pharmaceuticals Source Type: news

Family travels 7,500 miles to save son ’s life with treatment developed at UCLA
When he was born in September 2015, Hussein El Kerdi looked like a healthy baby boy. No one knew that his immune cells lacked an important enzyme. But the absence of that enzyme would profoundly change the El Kerdi family ’s life, sending them on a journey from their small hometown in Lebanon to UCLA. Their one goal: to save Hussein’s life.When Hussein was three months old, a physician in Beirut diagnosed Hussein with a life-threatening immune disorder called adenosine deaminase-deficient severe combined immunodeficiency, also known as ADA-SCID or bubble baby disease.The disorder is caused by a genetic mutation...
Source: UCLA Newsroom: Health Sciences - June 28, 2018 Category: Universities & Medical Training Source Type: news

A Hat Trick Of Cell And Gene Therapy IPOs: AVRO, MGTA, and UMRX
Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three are cell and gene therapy biotechs. The author shares his reflections on those companies, the markets, and the cell& gene therapy space (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 28, 2018 Category: Pharmaceuticals Authors: Bruce Booth, Contributor Tags: NASDAQ:UMRX NASDAQ:MGTA NASDAQ:AVRO Source Type: news

Turning pancreatic alpha cells into insulin-producing beta-like cells via gene therapy
Scientists have developed a new way to replace lost beta cells in mouse models of type 1 diabetes.  (Source: NIDDK News)
Source: NIDDK News - June 26, 2018 Category: Endocrinology Source Type: news

SNMMI: Fluciclovine-PET changes prostate treatment
PHILADELPHIA - With the addition of F-18 fluciclovine to PET/CT scans, clinicians...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: Molecular imaging method monitors gene therapy Blue Earth promotes results for PET/CT agent Blue Earth touts addition of Axumin to NCCN guidelines Novel PET tracer aids recurrent prostate cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 26, 2018 Category: Radiology Source Type: news

SNMMI: Molecular imaging method monitors gene therapy
PHILADELPHIA - A new molecular imaging method can monitor the level and location...Read more on AuntMinnie.comRelated Reading: SNMMI: AI can avoid patient misidentification on PET/CT SNMMI: New therapy aids patients with neuroendocrine tumors SNMMI 2018: A year of promotion and ongoing challenges Machine learning may identify medulloblastoma subtypes DWI-MRI could help show gene expression in tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 26, 2018 Category: Radiology Source Type: news